HALO

No analysis generated yet. Run the pipeline for this company.

AI-extracted key facts from press releases and SEC filings. Significance 1–10.

8

GuidanceBullishPer-CompanyMar 18, 2026

Halozyme Forecasts $1.7B-$1.8B Revenue for 2026, 22%-30% YoY Growth

▸FY26 revenue guidance $1.7B–$1.8B, representing 22%–30% YoY growth
▸Royalty revenue projected at $1.1B–$1.2B, growing 30%–35%
▸Adjusted EBITDA forecast of $1.1B–$1.2B
▸Darzalex FASPRO, VYVGART Hytrulo, and Perjeta identified as primary growth drivers
▸Roche targeting 60% conversion to subcutaneous Perjeta by 2028

Halozyme